SEARCH:   Advanced

Blood, 15 September 2005, Vol. 106, No. 6, pp. 2162-2168. Prepublished online as a Blood First Edition Paper on May 26, 2005; DOI 10.1182/blood-2005-03-1320. This Article Full Text (PDF) All Versions of this Article: 2005-03-1320v1 106/6/2162    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Jones, A. V Articles by Cross, N. C Search for Related Content PubMed PubMed Citation Articles by Jones, A. V Articles by Cross, N. C Related Collections Related Letters in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 31, 2005 Accepted May 16, 2005 Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders Amy V Jones, Sebastian Kreil, Katerina Zoi, Katherine Waghorn, Claire Curtis, Lingyan Zhang, Joannah Score, Rachel Seear, Andrew J Chase, Francis H Grand, Helen White, Christine Zoi, Dimitris Loukopoulos, Evangelos Terpos, Elisavet-Christine Vervessou, Beate Schultheis, Michael Emig, Thomas Ernst, Eva Lengfelder, Rudiger Hehlmann, Andreas Hochhaus, David Oscier, Richard T Silver, Andreas Reiter, and Nicholas C Cross* Wessex Regional Genetics Laboratory, UK and Human Genetics Division, University of Southampton, Salisbury, United Kingdom Foundation of Biomedical Research of Academy of Athens, Athens, Greece General Airforce Hospital, Athens, Greece "Errikos Dynan" Athens General Hospital, Athens, Greece III. Medizinische Universitatsklinik, Fakultat fur Klinische Medizin Mannheim der Universitat Heidelberg, Mannheim, Germany Royal Bournemouth Hospital, Bournemouth, United Kingdom Weill Medical College of Cornell University, New York, NY, USA * Corresponding author; email: ncpc{at}soton.ac.uk. The analysis of rare chromosomal translocations in myeloproliferative disorders has highlighted the importance of aberrant tyrosine kinase signalling in the pathogenesis of these diseases. Here we have investigated samples from 679 patients and controls for the non-receptor tyrosine kinase JAK2 V617F mutation. Of the 480 MPD samples, the proportion of positive cases per disease subtype was atypical or unclassified MPD 30/152 (20%), idiopathic hypereosinophilic syndrome 2/134 (2%), polycythemia vera 58/72 (81%), essential thrombocythemia 24/59 (41%) and idiopathic myelofibrosis 15/35 (43%). V617F was not identified in patients with systemic mastocytosis (n=28), chronic or acute myeloid leukemia (n=35), secondary erythrocytosis (n=4) or normal controls (n=160). Homozygosity for V617F was seen in 43% of mutant samples and closely correlated with chromosome 9p uniparental disomy. Homozygosity was significantly less common in ET compared to other MPD subtypes. In 53 cases analysed, the median level of PRV1 expression was significantly higher in V617F positive cases compared to cases without the mutation. We conclude that V617F is widespread in MPDs. Detection of this acquired mutation is likely to have a major impact on the way MPD patients are diagnosed, as well as serving as an obvious target for signal transduction therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letters in Blood Online: A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples Martin Sattler, Christoph Walz, Brian J. Crowley, Eva Lengfelder, Pasi A. Jänne, Andrew M. Rogers, Yanan Kuang, Robert J. Distel, Andreas Reiter, and James D. Griffin Blood 2006 107: 1237-1238. [Full Text] [PDF] Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7 Stefan Fröhling, Daniel B. Lipka, Sabine Kayser, Claudia Scholl, Richard F. Schlenk, Hartmut Döhner, D. Gary Gilliland, Ross L. Levine, and Konstanze Döhner Blood 2006 107: 1242-1243. [Full Text] [PDF] This article has been cited by other articles: A. Quintas-Cardama, H. Kantarjian, T. Manshouri, R. Luthra, Z. Estrov, S. Pierce, M. A. Richie, G. Borthakur, M. Konopleva, J. Cortes, et al. Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera J. Clin. Oncol., November 10, 2009; 27(32): 5418 - 5424. [Abstract] [Full Text] [PDF] M. Cankovic, L. Whiteley, R. C. Hawley, R. J. Zarbo, and D. Chitale Clinical Performance of JAK2 V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory: Evaluation of Screening and Quantitation Methods Am J Clin Pathol, November 1, 2009; 132(5): 713 - 721. [Abstract] [Full Text] [PDF] J. W. Vardiman, J. Thiele, D. A. Arber, R. D. Brunning, M. J. Borowitz, A. Porwit, N. L. Harris, M. M. Le Beau, E. Hellstrom-Lindberg, A. Tefferi, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood, July 30, 2009; 114(5): 937 - 951. [Abstract] [Full Text] [PDF] F. H. Grand, C. E. Hidalgo-Curtis, T. Ernst, K. Zoi, C. Zoi, C. McGuire, S. Kreil, A. Jones, J. Score, G. Metzgeroth, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms Blood, June 11, 2009; 113(24): 6182 - 6192. [Abstract] [Full Text] [PDF] S. A. Gustafson, P. Lin, S. S. Chen, L. Chen, L. V. Abruzzo, R. Luthra, L. J. Medeiros, and S. A. Wang Therapy-Related Acute Myeloid Leukemia With t(8;21) (q22;q22) Shares Many Features With De Novo Acute Myeloid Leukemia With t(8;21)(q22;q22) but Does Not Have a Favorable Outcome Am J Clin Pathol, May 1, 2009; 131(5): 647 - 655. [Abstract] [Full Text] [PDF] I. Rapado, S. Grande, E. Albizua, R. Ayala, J.-A. Hernandez, M. Gallardo, F. Gilsanz, and J. Martinez-Lopez High Resolution Melting Analysis for JAK2 Exon 14 and Exon 12 Mutations: A Diagnostic Tool for Myeloproliferative Neoplasms J. Mol. Diagn., March 1, 2009; 11(2): 155 - 161. [Abstract] [Full Text] [PDF] H. Andrikovics, N. Meggyesi, A. Szilvasi, J. Tamaska, G. Halm, S. Lueff, S. Nahajevszky, M. Egyed, J. Varkonyi, G. Mikala, et al. HFE C282Y Mutation as a Genetic Modifier Influencing Disease Susceptibility for Chronic Myeloproliferative Disease Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 929 - 934. [Abstract] [Full Text] [PDF] S. Verstovsek New Therapeutic Options for Myelofibrosis ASCO Educational Book, January 1, 2009; 2009(1): 426 - 429. [Abstract] [Full Text] [PDF] R. Zhao, G. A. Follows, P. A. Beer, L. M. Scott, B. J.P. Huntly, A. R. Green, and D. R. Alexander Inhibition of the Bcl-xL Deamidation Pathway in Myeloproliferative Disorders N. Engl. J. Med., December 25, 2008; 359(26): 2778 - 2789. [Abstract] [Full Text] [PDF] J. L. Spivak and R. T. Silver The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal Blood, July 15, 2008; 112(2): 231 - 239. [Full Text] [PDF] S. Xing, T. H. Wanting, W. Zhao, J. Ma, S. Wang, X. Xu, Q. Li, X. Fu, M. Xu, and Z. J. Zhao Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice Blood, May 15, 2008; 111(10): 5109 - 5117. [Abstract] [Full Text] [PDF] Z. Xiang, Y. Zhao, V. Mitaksov, D. H. Fremont, Y. Kasai, A. Molitoris, R. E. Ries, T. L. Miner, M. D. McLellan, J. F. DiPersio, et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia Blood, May 1, 2008; 111(9): 4809 - 4812. [Abstract] [Full Text] [PDF] P. M. Mannucci and F. Peyvandi Thrombophilia Screening: Little Role for the JAK2V617F Mutation Mayo Clin. Proc., April 1, 2008; 83(4): 398 - 399. [Full Text] [PDF] G. Wernig, J. R. Gonneville, B. J. Crowley, M. S. Rodrigues, M. M. Reddy, H. E. Hudon, C. Walz, A. Reiter, K. Podar, Y. Royer, et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes Blood, April 1, 2008; 111(7): 3751 - 3759. [Abstract] [Full Text] [PDF] D. P. Steensma and A. Tefferi JAK2 V617F and ringed sideroblasts: not necessarily RARS-T Blood, February 1, 2008; 111(3): 1748 - 1748. [Full Text] [PDF] D. Pietra, S. Li, A. Brisci, F. Passamonti, E. Rumi, A. Theocharides, M. Ferrari, H. Gisslinger, R. Kralovics, L. Cremonesi, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders Blood, February 1, 2008; 111(3): 1686 - 1689. [Abstract] [Full Text] [PDF] C. James The JAK2V617F Mutation in Polycythemia Vera and Other Myeloproliferative Disorders: One Mutation for Three Diseases? Hematology, January 1, 2008; 2008(1): 69 - 75. [Abstract] [Full Text] [PDF] R. L. Levine and M. Heaney New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia Hematology, January 1, 2008; 2008(1): 76 - 82. [Abstract] [Full Text] [PDF] J. W. Vardiman Integration of Histology and Genetics in the Diagnosis and Classification of Myeloproliferative Neoplasms ASCO Educational Book, January 1, 2008; 2008(1): 339 - 345. [Abstract] [Full Text] [PDF] M. J. Percy, L. M. Scott, W. N. Erber, C. N. Harrison, J. T. Reilly, F. G.C. Jones, A. R. Green, and M. F. McMullin The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels Haematologica, December 1, 2007; 92(12): 1607 - 1614. [Abstract] [Full Text] [PDF] A. Pradhan, Q. T. Lambert, and G. W. Reuther Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor PNAS, November 20, 2007; 104(47): 18502 - 18507. [Abstract] [Full Text] [PDF] R. Chaligne, C. James, C. Tonetti, R. Besancenot, J. P. Le Couedic, F. Fava, F. Mazurier, I. Godin, K. Maloum, F. Larbret, et al. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis Blood, November 15, 2007; 110(10): 3735 - 3743. [Abstract] [Full Text] [PDF] G. Helbig, B. Stella-Holowiecka, M. Majewski, M. Lewandowska, and J. Holowiecki Interferon {alpha} induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation Haematologica, November 1, 2007; 92(11): e118 - e119. [Abstract] [Full Text] [PDF] A. Reiter, D. Grimwade, and N. C.P. Cross Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders Haematologica, September 1, 2007; 92(9): 1153 - 1158. [Full Text] [PDF] A. Tefferi, J. Thiele, A. Orazi, H. M. Kvasnicka, T. Barbui, C. A. Hanson, G. Barosi, S. Verstovsek, G. Birgegard, R. Mesa, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Blood, August 15, 2007; 110(4): 1092 - 1097. [Abstract] [Full Text] [PDF] A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Rambaldi, G. Barosi, R. Marchioli, R. M. Marfisi, G. Finazzi, V. Guerini, F. Fabris, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia Blood, August 1, 2007; 110(3): 840 - 846. [Abstract] [Full Text] [PDF] M.-P. Wautier, W. El Nemer, P. Gane, J.-D. Rain, J.-P. Cartron, Y. Colin, C. Le Van Kim, and J.-L. Wautier Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin {alpha}5 chain and Lu/BCAM Blood, August 1, 2007; 110(3): 894 - 901. [Abstract] [Full Text] [PDF] A. J. Walne, T. Vulliamy, A. Marrone, R. Beswick, M. Kirwan, Y. Masunari, F.-h. Al-Qurashi, M. Aljurf, and I. Dokal Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10 Hum. Mol. Genet., July 1, 2007; 16(13): 1619 - 1629. [Abstract] [Full Text] [PDF] G. Finazzi and T. Barbui How I treat patients with polycythemia vera Blood, June 15, 2007; 109(12): 5104 - 5111. [Abstract] [Full Text] [PDF] A. Tefferi and A. Pardanani Evaluation of 'Increased' Hemoglobin in the JAK2 Mutations Era: A Diagnostic Algorithm Based on Genetic Tests Mayo Clin. Proc., May 1, 2007; 82(5): 599 - 604. [Abstract] [Full Text] [PDF] S. Fletcher and B. Bain Eosinophilic leukaemia Br. Med. Bull., April 18, 2007; (2007) ldm008v1. [Abstract] [Full Text] [PDF] E. Hammond, K. Shaw, B. Carnley, S. P'ng, I. James, and R. Herrmann Quantitative Determination of JAK2 V617F by TaqMan: An Absolute Measure of Averaged Copies per Cell That May Be Associated with the Different Types of Myeloproliferative Disorders J. Mol. Diagn., April 1, 2007; 9(2): 242 - 248. [Abstract] [Full Text] [PDF] Q. Chen, P. Lu, A. V. Jones, N. C.P. Cross, R. T. Silver, and Y. L. Wang Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders J. Mol. Diagn., April 1, 2007; 9(2): 272 - 276. [Abstract] [Full Text] [PDF] L. Teofili, F. Giona, M. Martini, T. Cenci, F. Guidi, L. Torti, G. Palumbo, A. Amendola, R. Foa, and L. M. Larocca Markers of Myeloproliferative Diseases in Childhood Polycythemia Vera and Essential Thrombocythemia J. Clin. Oncol., March 20, 2007; 25(9): 1048 - 1053. [Abstract] [Full Text] [PDF] Z. Li, M. Xu, S. Xing, W. T. Ho, T. Ishii, Q. Li, X. Fu, and Z. J. Zhao Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth J. Biol. Chem., February 9, 2007; 282(6): 3428 - 3432. [Abstract] [Full Text] [PDF] E. C. Wolstencroft, K. Hanlon, L. W. Harries, G. R. Standen, A. Sternberg, and S. Ellard Development of a Quantitative Real-Time Polymerase Chain Reaction Assay for the Detection of the JAK2 V617F Mutation J. Mol. Diagn., February 1, 2007; 9(1): 42 - 46. [Abstract] [Full Text] [PDF] A. Tefferi JAK2 Mutations in Polycythemia Vera -- Molecular Mechanisms and Clinical Applications N. Engl. J. Med., February 1, 2007; 356(5): 444 - 445. [Full Text] [PDF] L. M. Scott, W. Tong, R. L. Levine, M. A. Scott, P. A. Beer, M. R. Stratton, P. A. Futreal, W. N. Erber, M. F. McMullin, C. N. Harrison, et al. JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis N. Engl. J. Med., February 1, 2007; 356(5): 459 - 468. [Abstract] [Full Text] [PDF] C. Walz, G. Metzgeroth, C. Haferlach, A. Schmitt-Graeff, A. Fabarius, V. Hagen, O. Prummer, S. Rauh, R. Hehlmann, A. Hochhaus, et al. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor {beta} gene Haematologica, February 1, 2007; 92(2): 163 - 169. [Abstract] [Full Text] [PDF] R. E. Gale, A. J.R. Allen, M. J. Nash, and D. C. Linch Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years Blood, February 1, 2007; 109(3): 1241 - 1243. [Abstract] [Full Text] [PDF] C. L. Andersen, C. Wiuf, M. Kruhoffer, M. Korsgaard, S. Laurberg, and T. F. Orntoft Frequent occurrence of uniparental disomy in colorectal cancer Carcinogenesis, January 1, 2007; 28(1): 38 - 48. [Abstract] [Full Text] [PDF] K. Brakensiek, L. U. Wingen, F. Langer, H. Kreipe, and U. Lehmann Quantitative High-Resolution CpG Island Mapping with PyrosequencingTM Reveals Disease-Specific Methylation Patterns of the CDKN2B Gene in Myelodysplastic Syndrome and Myeloid Leukemia Clin. Chem., January 1, 2007; 53(1): 17 - 23. [Abstract] [Full Text] [PDF] F. Delhommeau, S. Dupont, C. Tonetti, A. Masse, I. Godin, J.-P. L. Couedic, N. Debili, P. Saulnier, N. Casadevall, W. Vainchenker, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis Blood, January 1, 2007; 109(1): 71 - 77. [Abstract] [Full Text] [PDF] X. Xu, Q. Zhang, J. Luo, S. Xing, Q. Li, S. B. Krantz, X. Fu, and Z. J. Zhao JAK2V617F: prevalence in a large Chinese hospital population Blood, January 1, 2007; 109(1): 339 - 342. [Abstract] [Full Text] [PDF] P. J. Campbell and A. R. Green The Myeloproliferative Disorders N. Engl. J. Med., December 7, 2006; 355(23): 2452 - 2466. [Full Text] [PDF] T. G.P. Bumm, C. Elsea, A. S. Corbin, M. Loriaux, D. Sherbenou, L. Wood, J. Deininger, R. T. Silver, B. J. Druker, and M. W.N. Deininger Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease Cancer Res., December 1, 2006; 66(23): 11156 - 11165. [Abstract] [Full Text] [PDF] A. R. Moliterno, D. M. Williams, O. Rogers, and J. L. Spivak Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression Blood, December 1, 2006; 108(12): 3913 - 3915. [Abstract] [Full Text] [PDF] P. J. Campbell, E. J. Baxter, P. A. Beer, L. M. Scott, A. J. Bench, B. J. P. Huntly, W. N. Erber, R. Kusec, T. S. Larsen, S. Giraudier, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation Blood, November 15, 2006; 108(10): 3548 - 3555. [Abstract] [Full Text] [PDF] H. Szpurka, R. Tiu, G. Murugesan, S. Aboudola, E. D. Hsi, K. S. Theil, M. A. Sekeres, and J. P. Maciejewski Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation Blood, October 1, 2006; 108(7): 2173 - 2181. [Abstract] [Full Text] [PDF] D. P. Steensma JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2006; 8(4): 397 - 411. [Abstract] [Full Text] [PDF] T. Horn, M. Kremer, T. Dechow, W. M. Pfeifer, B. Geist, M. Perker, J. Duyster, L. Quintanilla-Martinez, and F. Fend Detection of the Activating JAK2 V617F Mutation in Paraffin-Embedded Trephine Bone Marrow Biopsies of Patients with Chronic Myeloproliferative Diseases J. Mol. Diagn., July 1, 2006; 8(3): 299 - 304. [Abstract] [Full Text] [PDF] M. Lay, R. Mariappan, J. Gotlib, L. Dietz, S. Sebastian, I. Schrijver, and J. L. Zehnder Detection of the JAK2 V617F Mutation by LightCycler PCR and Probe Dissociation Analysis J. Mol. Diagn., July 1, 2006; 8(3): 330 - 334. [Abstract] [Full Text] [PDF] P. Sidon, P. Heimann, F. Lambert, B. Dessars, V. Robin, and H. El Housni Combined Locked Nucleic Acid and Molecular Beacon Technologies for Sensitive Detection of the JAK2V617F Somatic Single-Base Sequence Variant. Clin. Chem., July 1, 2006; 52(7): 1436 - 1438. [Full Text] [PDF] G. Wernig, T. Mercher, R. Okabe, R. L. Levine, B. H. Lee, and D. G. Gilliland Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model Blood, June 1, 2006; 107(11): 4274 - 4281. [Abstract] [Full Text] [PDF] R. L. Levine, C. Belisle, M. Wadleigh, D. Zahrieh, S. Lee, P. Chagnon, D. G. Gilliland, and L. Busque X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis Blood, May 15, 2006; 107(10): 4139 - 4141. [Abstract] [Full Text] [PDF] H. Walczak Polycythemia vera erythroblasts: too tough to die Blood, May 1, 2006; 107(9): 3422 - 3423. [Full Text] [PDF] A. Zeuner, F. Pedini, M. Signore, G. Ruscio, C. Messina, A. Tafuri, G. Girelli, C. Peschle, and R. De Maria Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells Blood, May 1, 2006; 107(9): 3495 - 3502. [Abstract] [Full Text] [PDF] A. V. Jones, R. T. Silver, K. Waghorn, C. Curtis, S. Kreil, K. Zoi, A. Hochhaus, D. Oscier, G. Metzgeroth, E. Lengfelder, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha Blood, April 15, 2006; 107(8): 3339 - 3341. [Abstract] [Full Text] [PDF] A. Tefferi, M. A. Elliott, and A. Pardanani Atypical Myeloproliferative Disorders: Diagnosis and Management Mayo Clin. Proc., April 1, 2006; 81(4): 553 - 563. [Abstract] [Full Text] [PDF] D. P. Steensma, A. Pardanani, W. S. Stevenson, R. Hoyt, H. Kiu, A. P. Grigg, J. Szer, S. Juneja, D. J. Hilton, W. S. Alexander, et al. More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders Blood, February 15, 2006; 107(4): 1733 - 1735. [Full Text] [PDF] R. L. Levine and G. Wernig Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders Hematology, January 1, 2006; 2006(1): 233 - 239. [Abstract] [Full Text] [PDF] A. Tefferi Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F Era Hematology, January 1, 2006; 2006(1): 240 - 245. [Abstract] [Full Text] [PDF] A. Tefferi V617F "JAKs" up myeloproliferative signal Blood, November 15, 2005; 106(10): 3335 - 3336. [Full Text] [PDF] R. L. Levine, M. Loriaux, B. J. P. Huntly, M. L. Loh, M. Beran, E. Stoffregen, R. Berger, J. J. Clark, S. G. Willis, K. T. Nguyen, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia Blood, November 15, 2005; 106(10): 3377 - 3379. [Abstract] [Full Text] [PDF] A. T. Look Molecular Pathogenesis of MDS Hematology, January 1, 2005; 2005(1): 156 - 160. [Abstract] [Full Text] [PDF] W. Vainchenker and S. N. Constantinescu A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases Hematology, January 1, 2005; 2005(1): 195 - 200. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020